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 Mitotic cell division is critically reliant on consistent and faithful segregation of 
genetic information into newly forming daughter cells. Any perturbation in this process 
can have catastrophic intracellular effects and as such, many natural mechanisms occur 
during mitosis to prevent these anomalous events. Kinesins make up 14 families of motor 
proteins, using ATP-driven movement along microtubules to fulfill a range of functions, 
including organelle and vesicular transport. One such kinesin, plus-end directed KIF18A 
of the Kinesin 8 family, has been extensively investigated and found to be critically 
associated with restricting chromosome oscillation during chromosome alignment at the 
metaphase plate. Depletion of KIF18A subtly increases mitotic duration, chromosome 
oscillations, lagging chromosomes, and micronucleus formation in normal diploid cells 
and has minimal effects on cell viability. By contrast, loss of Kif18A induces severe 
mitotic defects that significantly impair viability in whole genome-doubled and highly 
aneuploid cells. As tetraploidization or whole genome doubling has been linked to large 
percentages of cancer types, this dependence on KIF18A has been proposed as a possible 
therapeutic target for cancer treatment. Two known KIF18A inhibitors exist; however, 
their function is either limited (BTB-1) or the efficacy remains to be publicly validated 
(Amgen). In this thesis, a screening protocol involving fluorescent-based live cell 
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imaging was formulated to test several small molecule compounds that were suspected to 
have compatibilities with a binding site on KIF18A. Through the screening process, 
Compound 3 was identified and found to demonstrate a phenotype similar to KIF18A 
depletion—prolonged mitosis, decreased cell proliferation/viability, and induction of 
chromosome oscillation. Further examination of this compound as a potential therapeutic 
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The Cell Cycle and Entry into Mitosis 
 
Mitotic cell division is an evolutionarily conserved mechanism among eukaryotic 
cells, with a functional endpoint of generating two identical “daughter” cells from the 
original “parental” cell; thereby allowing for replacement and expansion of a cell lineage 
(1,3,4,8). Mitosis is the last stage of the eukaryotic cell cycle, conventionally called the 
cell cycle or mitotic cycle, the overall process involves two distinct phases--interphase 
and mitosis--with key regulatory checkpoints at most transitions between phases or 
subsequent subphases (1,9,22). Critical to the cell cycle is the consistent unidirectionality 
under normal circumstances that is predominantly reliant on a wide range of intracellular 
signaling molecules; the prominent cell signals being stage-specific cyclin and cyclin 
dependent kinase (CDK) levels (34). The cell cycle begins with a period referred to as 
“interphase”, in which the cell synthesizes necessary cellular components and replicates 
its DNA in order to provide the necessary elements to each subsequent daughter cell after 
cytokinesis (2,5). For a cycling cell, it will spend approximately 90% of its life cycle in 
interphase (38).  
Classically, interphase is composed of 3 subphases, the first of which is referred 
to as a “gap” and is conventionally called “G1”. During G1, the cell is transcriptionally 
active and generates the necessary replicative components as it prepares for DNA 
replication (5,9). At a point during G1, the cell will pass through its first key regulatory 
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checkpoint, referred to as the “restriction point” or “R-point”, where the cell ensures that 
it is suitable for continuing through and capable of completing mitosis--the alternative of 
which is entry into a non-cycling or quiescent state known as “G0” (9-11,21,34,46). 
Surrounding signaling molecules, such as growth factors, mitogenic signals, and local 
nutrient levels, ensure proper passage through this restriction point; their removal leading 
to G0 and supplementation leading back to the same point of G1 prior to exit (43,46).  
A major regulator in this portion of the cell cycle is the retinoblastoma (RB) 
family of proteins which preferentially regulate E2F transcription factors and cyclin 
dependent kinases (CDKs) (14,16,17,19,42). In short, the E2F transcription factors are 
segregated in a complex with RB protein until sufficient elevation of cyclin-D levels 
complex with CDK4 and CDK6 (101-103). At sufficiently high levels, the cyclin-D 
CDK4/6 complex can partially phosphorylate many residues on RB protein, thus 
releasing E2F transcription factors to then facilitate transcription of cell progression 
genes related to S-phase (101-103). After partial phosphorylation of RB, cyclin E levels 
are able to rise and interact with CDK2, which leads to further phosphorylation and 
inactivation of the RB protein (102,103). After passing the regulation by RB through 
phosphorylation, and thus passing this restriction point, the cell becomes irreversibly 
committed to cell division; although completion is dependent on the successful DNA 
replication, which is monitored under normal circumstances by subsequent checkpoints 
and monitors of cellular/DNA damage (3,14,21,34,48). The lynchpin monitor is the 
tumor-suppressor protein p53, interacting through several mechanisms to drive controlled 
cellular death via apoptosis when damage is detected (43,46).  
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The next subphase, denoted synthesis phase or “S phase”, covers the period of 
genomic replication, occurring in a semiconservative fashion, to form sister chromatids 
which can eventually be equally separated into the respective daughter cells; essential to 
this replicative process is the faithful duplication while maintaining cohesion of the 
newly formed pairs, called sister chromatids, via points of cellular linkage called 
centromeres (30,33,35,38,51). Replication is tightly regulated, thus preventing or 
minimizing error, and failure of this regulation can lead to a range of catastrophic cellular 
events instantaneously or over time, including chromosome damage, cellular necrosis, 
aneuploidy, or cancer (6,20,21,32,43).  
Upon complete replication of the parental cell’s genome, the cell enters a second 
“gap” referred to as “G2” (1). In G2, the cell continues to develop the necessary 
machinery and cellular components to sustain both cell division and proliferative capacity 
for both subsequent daughter cells and begins to prepare for division (43). Prior to entry 
into mitosis, the cell must first pass an internal quality control mechanism referred to 
conventionally as the “G2/M checkpoint” in which regulatory mechanisms ensure that 
the cell has properly replicated its DNA and is prepared for the final stage of the cell 
cycle (42,43,47).  
Mitosis 
 
After clearing the preceding checkpoints, the cell is now prepared to enter mitosis. 
This entry relies most heavily on the activation and subsequent activity of cyclin B and 
cyclin-dependent kinase 1 (CDK1) (28,29,31). Numerous macroscopic and architectural 
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changes occur, including cellular rounding/swelling and cytoskeletal rearrangements, 
allowing for proper division of cellular organelles and genetic material (28,29). This 
phase of the cell cycle is divided conventionally into 5 subphases: prophase, 
prometaphase, metaphase, anaphase, and telophase (38). After accumulation of cyclin B-
CDK1 complexes to a threshold of approximately 30%, autocatalysis will further increase 
the complex concentration and initiate entry into prophase (40). This mechanism 
coincides with a nuclear translocation of the cyclin B-CDK1 complex, a result of 
phosphorylation on its cytoplasmic retention sequence thus eliminating this cytoplasmic 
restriction (40).  
During prophase and continuing through prometaphase, the mitotic cell begins to 
condense its genetic material into structures called chromosomes, which are resolvable 
due to segregating forces of condensin proteins—composed of structural maintenance of 
chromosome (SMC) subunits—that facilitate formation of a “rod-like” structure (51,58). 
Coinciding with this condensation into chromosomes, the nuclear envelope, which 
normally surrounds the non-condensed genetic material, begins to break down; a requisite 
is the detachment of the condensing sister chromatids from the nuclear envelope prior to 
its breakdown (42). The general process can be visualized in Figure 1, which is a series of 
images taken from Gibcus et al in which selectively arrested cycling cells are released 
into mitosis to visualize the architectural changes of genetic material during early 






Figure 1: Chromosome morphogenesis during synchronized mitosis.  
Visualization by photo-microscopy of 4′,6-diamidino-2-phenylindole (DAPI), which 
selectively highlights genetic material through interactions in A-T rich sequences in 
condensed and non-condensed DNA (41). All time points refer to minutes after release from 
CDK1-inhibited arrest during G2. NEBD: Nuclear Envelope Break Down. Image adapted 
from Gibcus et al.(2018) (38). 
 
The next phase of mitosis, prometaphase, is signified by the interaction of 
chromosomes with microtubules—polarized (“(+)” for plus-end and “(-)” for minus-end) 
tubular polymers of α and ß tubulin protein subunits—through the binding at centromere 
structures called kinetochores (39,45,52,55). To allow for this highly dynamic 
interaction, the cell assembles structures referred to as spindles (104). Coinciding with 
nuclear envelope breakdown, nucleating centers called microtubule organizing centers 
(MTOCs) are replicated at the nuclear envelope; the most frequently described MTOC 
being the centrosome—which is composed of orthogonal centrioles and a protein matrix 
called pericentriolar material (PCM) (104-106). At nuclear envelope breakdown, these 
replicated centrosomes move to opposite ends of the cell and interact with a wide range 
of recruiting factors and associated proteins, including molecular scaffolds like γ-Tubulin 
Ring Complexes (γ-TuRCs) (104-106).  
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In order to ensure a tightly regulated process, the prometaphase chromosomes will 
ensure the formation of the mitotic checkpoint complex (MCC), composed of several 
protein subunits (BubR1, Bub3, Mad2, Cdc20) (55). The predominant function of this 
complex is to inhibit the activity of the “anaphase promoting complex or cyclosome 
(APC/C)” until necessary chromosomal bindings/orientations are satisfied (3,53).  
Mitotic microtubules are often arranged into 13 protofilaments formed in a “head-
to-tail” orientation and, together with the two microtubule organizing centers that 
nucleate their propagation, comprise the mitotic spindle (53). Distinct types of 
microtubules (astral, kinetochore, and interpolar) allow for accurate and precise 
organization of the chromosomes during the next phase of the cell cycle, metaphase 
(13,52,53). Kinetochore microtubules, with their (+)-end attached to the chromosomes at 
the centromere and (-)-end attached to the nucleating centrosome, provide the connection 
between MTOCs and chromosomes (13,52,53). The astral microtubules can function to 
either help to generate the bipolar orientation of the cell as they anchor to the cellular 
cortex or to be “captured” by the centromere/kinetochore region (53,54). The final 
interpolar microtubules interact with other interpolar microtubules from opposing 
centrosomes to establish a gradient of distance and establish a “midzone” onto which 
chromosomes can be aligned (53,54). Alignment in of the chromosomes in the midzone, 
with one of each sister chromatid being attached to an opposing pole, is critical to ensure 
faithful and equal division of these genetic components into the subsequent daughter 
cells. A visual representation of this prometaphase/metaphase microtubule dynamics can 




Figure 2: Visualization of Microtubules During Prometaphase/Metaphase 
Simplified rendering of various types of microtubules as they interact during early-phase 
mitosis. (+) denotes plus-end microtubules which are faster growing than (-) denoted minus-
end microtubules. MT: Microtubule. Image taken from Fraschini (2017). 
 
Mitotic microtubules will normally be in a relatively dynamic state, generating 
opposing pushing and pulling forces on the attached chromosomes as they are aligned at 
a central region referred to as the “metaphase plate” (51-55). Integral to their movement, 
attachment, and dynamics, are a series of proteins, called microtubule-associated proteins 
(MAPs) and a specialized subset of motor proteins (kinesins and dyneins) (51-55). Up 
until proper alignment, the sister chromatids remain securely attached by a structural 
protein called cohesin (51-55). Cohesin will be maintained through several regulatory 
mechanisms under control of a regulatory checkpoint referred to as the “spindle assembly 
checkpoint” (SAC) or “mitotic/metaphase checkpoint” (56). After the SAC is adequately 
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satisfied, the next phase, anaphase, is marked by a release of APC/C inhibition and 
subsequent degradation by ubiquitination of cyclin-B and a regulatory protein called 
securin (51-56). An overview of these dynamics can be seen in Figure 3. 
 
Figure 3: Diagrammatic Overview of SAC Mechanisms 
A) Simplified mechanistic and biochemical interplay of key regulatory activators and 
inhibitors that ensure faithful progression through mitosis at each mitotic subphase. 
Activated SAC can be seen due to unattached kinetochore preventing Cdc20 from being 
able to dissociate from the MCC and interact with the APC/C complex, thus further mitotic 
progression to anaphase. B) Interchanging dynamics dependent on current kinetochore 
attachment or alignment affecting SAC status. Image taken from Musacchio (2015) (56). 
 
The liberation of the protease separase via securin proteolysis initiates the 
cleavage of cohesin at the Scc1 subunit and denotes the start of anaphase, an irreversible 
event that inevitably leads to completion of mitosis (3,56). Improper passage through this 
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checkpoint or the presence of additional centrosomes has the possibility of leading to 
segregation errors, aneuploidy, and subsequently tumorigenesis under certain pro-
cancerous conditions (57). Within minutes of the dissolution of cohesin, chromosome 
separation generates two identical daughter cells. Coincident with this segregation, the 
degradation of cyclin B triggers the cell to transition out of mitosis as the requisite signal 
diminishes in quantity (3). Additionally, specific phosphatases (such as PP1 and PP2A) 
begin to accumulate in the cell and act to reverse many of the phosphorylation events that 
had resulted from the prior mitotic activity of cyclin/CDK complexes (59). After proper 
segregation of chromosomes, several reverse processes to those in early mitosis occur—
decondensation of the chromosomes, reformation of the nuclear envelope, and division of 
the cell by cytokinetic pinching of the plasma membrane (59).  
 
Kinesins – A General Overview 
Kinesin superfamily proteins (KIFs) are a family of motor proteins that use 
microtubules as a pathway on which they perform a wide range of functions. The primary 
function is an ATP-dependent transport of protein and organelle within the cell (62). This 
class of proteins was first identified in squid axons as a force-generating molecule that 
was irreversibly bound to microtubules when incubated with a nonhydrolyzable ATP 
analog (63). Since its discovery in 1985, varying subclasses of kinesins have been 
identified, categorized, and mechanistically manipulated (61). The 45 known kinesins 
genes were organized into 14 families based on monophyletically conserved groups 
(conventionally denoted Kinesin-# family, where # can be any number 1-14 as 
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determined by sequencing and/or structure; individual family member having often 
having the notation KIF@ where @ can be a combination of either numbers, letters, or 
both; ex. Kinesin-4 family member KIF4) (64,65-67). KIFs generally consist of two 
heavy and light chains; the heavy chains being a conserved motor/catalytic domain that is 
the site of microtubule binding (64,68). Upon alternating nucleotide binding to this motor 
domain, the kinesin can take 8 nm steps along the microtubules with relatively high 
processivity for a molecule of its size (64,65,70). Generally, the catalytic domain is found 
at the N-terminus and the KIF has plus-end directed motility; however, C-terminus 
catalytic domains with minus-end directed motility have been identified (65). Table 1 
below covers the various families, a subset from the given family, and some of the known 




Table 1: Kinesin Families and Functions.  
 








KIF5B, KHC, NKin, DdK3, 
DdK5 
Vesicle transport, conventional 
Kinesin-2 











Organelle transport, chromosome 
movement 
Kinesin-5 





KIF20, KIF23, Rab6Kinesin, 
CHO1, MKLP1 
Cytokinesis, spindle polarity 
Kinesin-7 
KIF10, CENP-E, CMET, 
CANA, KIP2 




Nuclear migration, mitochondrial 
transport 
Kinesin-9 KIF6, KIF9, KRP3, CrKLP1 Unclear 
Kinesin-10 KIF22, KID, Nod 
Chromosome segregation/helix–
hairpin–helix DNA-binding motif 
Kinesin-11 





KIF12, KIF15, HKLP2, 
KLP54D, Xklp2, PAKRPd 
Organelle transport/homologous tail 
Kinesin-13 










KIFC2, KIFC3, KatD, KCBP, 
KIF25 




Mitotic Kinesin – Kinesin 8 Family Member KIF18A 
 
 Although kinesins have been found to have a wide range of functions, about half 
have roles in mitosis, with Kinesin-8 and Kinesin-13 subfamilies having a critical control 
in microtubule dynamics (71,74).  The Kinesin-8 family has been identified as a 
“catastrophe promotor” due to the observed architectural changes associated with 
loss/mutation of the relevant kinesin. Although continuous alternation among a 
population of microtubules between growth and depolymerization, referred to as 
“dynamic instability”, is a common and normal feature of microtubules, “catastrophic” 
events, which refer to the shrinkage/depolymerization, tend to occur with increasing 
frequency in longer or older microtubules, as well as those which are being acted upon by 
a kinesin that accumulates at the plus-end (60,73,74,107-109). Specifically, Kinesin-8 
motors can be found localized to mitotic microtubules associated with the mitotic spindle, 
in a manner that is relatively evolutionarily conserved, and there are three known 
vertebrate family members: KIF18A, KIF18B, and KIF19 (74).  
 Kif18A (also known as Kip3p [yeast], Klp67A [D. melanogaster]), a plus-end 
directed motor, has garnered a particular interest, as its overexpression was found to have 
a poorer prognosis for both hepatocellular carcinoma and colorectal cancer (74,79-81). It 
was found that upon intracellular reduction of KIF18A by RNAi, chromosome 
congression was compromised, due to loss of microtubule depolymerizing activity, 
inducing “long mitotic spindles and loss of tension across sister kinetochores”; the 
consequence of which was a Mad2-dependent SAC activation (81). Work by Stumpff et 
al. (2008,2011,2012) confirmed previously found large oscillations in chromosomes at 
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the metaphase plate/equator would occur upon depletion of KIF18A and this was likely 
driven by a lack of KIF18A accumulation at plus-end mitotic microtubules and thus 
failure to suppress microtubule dynamics (78,82,83). Although KIF18A is significantly 
more abundant during mitosis and specifically both enriched and essential in many cancer 
types, KIF18A was found to be a non-essential gene and knockout mice lacking KIF18A 
had a normal lifespan (81,84). 
Whole Genome Doubling – Introducing a Vulnerability 
 As mentioned previously, mitosis is a tightly regulated process that requires 
faithful replication and separation of DNA equally into daughter cells—failure of such 
leading to abnormal chromosome count, referred to as chromosome instability (CIN) 
(96). Whole genome doubling (WGD) refers to an array of processes that produce a 
tetraploid cell from the natively diploid progenitor (84, 92). A suspected mechanism for 
tumorigenesis is through an intermediate tetraploid state, seeing as approximately 35-
40% of all human tumors experienced tetraploidization at a given point in their 
progression and correlate to a poorer prognosis (84,87,88,111). Through mechanisms 
such as mitotic slippage, cytokinesis failure, or viral-induced fusion, cells have been 
shown to capable of tetraploidization and, although rare, it is thus not unexpected for 
them to occur in natural systems given the sheer magnitude of cells and rate of turnover 
in an otherwise healthy organism (84,87,110).  
These WGD cells have been demonstrated to be tumorigenic in part due to 
selective pressures toward loss of key regulatory pathways, such as the p53 pathway or 
inflammatory processes, while upregulating processes that facilitate mitosis and DNA 
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repair (84). Accumulation of uncorrected mitotic errors, mutations, or DNA damage are 
often disadvantageous to a cell’s survival and should elicit a response from the many cell-
cycle controls—the potential buffering capacities of WFD to this genomic/chromosome 
instability, allows for survival of otherwise deleterious chromosomal abnormalities and 
can thus allow an oncogenic/proliferative cell that originates a neoplastic event (88, 
89,92). Additionally, given a WGD cell’s increased chromosomal content, they more 
frequently acquire “numerical and structural chromosomal abnormalities” (84,110). A 
suspected downstream product of WGD and hallmark of cancer, aneuploidy, is 
essentially ubiquitous among cancer cells and thus provides the most concerning 
endpoint for WGD cells (84,90-92). A visual representation of how tetraploid and 


















Figure 4: Production of Tetraploid and Near-Diploid Aneuploid Cells Following 
Cytokinesis Failure 
Simplified cell model where, following cytokinesis failure and generation of a binucleated 
tetraploid cell (G1 above), both near-tetraploid and near-diploid aneuploid cells can be 
generated following abnormal mitosis. Taken from Lens & Medema, 2019 (92). 
Although these WGD cells have selective pressures towards tumorigenic growth, 
they also have been found to have an increased dependence on certain mitotic proteins, 
such as KIF18A (84-86). The mechanism of KIF18A dependence was found to be due in 
large part to the hyperoscillating mitosis described previously by KIF18A depletion (84-
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86). Modulation of this hyperoscillation was found to be significantly essential, such that 
it was frequently upregulated in many WGD tumors (84). Despite the increased 
chromosome misalignment, diploid cells that lacked KIF18A were shown to segregate 
their chromosomes at a near normal level and a KIF18A knockout mouse survived to 
adulthood (84). This contrasts with isogenic-derived tetraploids, which experienced much 
more significant misalignment, lagging chromosomes, micronuclei formation, and 
micronuclei rupture; the increased spindle length and requisite distance traveled 
specifically in tetraploid cells being the major contributor to these deficits (84,85). They 
also experienced significantly prolonged mitoses, likely through activation via the SAC 
as there was a propensity for chromosome detachment from the mitotic spindle due to the 
hyperoscillation (84). As such, this introduces the possibility for therapeutic intervention, 
as there is the potential for decreasing the viability of WGD/aneuploid cancer cells while 
effectively sparing the near-diploid or diploid counterparts thus decreasing off-target 
side-effects commonly seen with cancer therapeutics such as Paclitaxel (84-86).  
Small Molecule Inhibition of KIF18A 
 Previous work by Catarinella et al. (2009) identified a compound, BTB-1, from a 
9000-compound inhibitor screen that could inhibit the ATPase activity of KIF18A in 
vitro (77). Screened at 50 μM concentration of various compounds on a recombinant 
KIF18A target, BTB-1was the most potent inhibitor and shown to reversibly compete 
with ATP binding in the motor domain (~90% inhibition at 100 μM dosing via enzyme 
assay and IC50 of 1.69 μM) (77). However, it was found that BTB-1 binds to KIF18A 
only when KIF18A itself was also bound to microtubules (77). Although BTB-1 
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inhibition of KIF18A promoted accumulation of HeLa cells in mitosis, the canonical 
elongated spindles seen via RNAi-mediated depletion was not seen, thus limiting the 
possible benefit to preferentially targeting WGD/highly-aneuploid tumor cells (77).  
 Further experimentation by Braun et al. (2015) and Locke et al. (2017) sought to 
modify BTB-1 to possibly increase its potency while restoring the elongated spindle 
phenotype, as well as further elucidating BTB-1’s binding/mechanism of action (74,76). 
Modifications, although able to increase the potency of BTB-1 to an extent, were unable 
to restore the associated spindle phenotype (76). It was determined as well that, although 
kinetically competitive, BTB-1 inhibition appears to act through an allosteric site on loop 
5 of KIF18A that is exposed upon binding to microtubules and hydrolyzing ATP, thus 
signaling the likely reason for its dependence on the microtubule-bound state for proper 
inhibition (74). There could also be additional consequences as the KIF18A was 
effectively locked to the microtubules, which has the potential to cause other defects and 
possibly impact near-diploid cells (74). As such, there remains reason to investigate other 
possible compounds that can act on both the microtubule-bound KIF18A and free 
KIF18A to properly confer WGD/highly aneuploid dependence.  
 It must also be noted that Amgen (Thousand Oaks, CA) has applied for and 
received a patent for a novel KIF18A inhibitor (93). At the time of generating this thesis, 
there is no readily available public knowledge or published research denoting its efficacy 
and as such further investigation remains warranted until that information is more widely 
available, and the compound is proven to be beneficial for in vitro and in vivo systems.  
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 Similar Kinesin Inhibition 
General kinesin inhibition has been achieved for other kinesins in microtubule 
bound and non-bound states; although they lack the desired specificity for WGD/highly-
aneuploid. For example, mitotic kinesin Eg5, also known as KIF11 or kinesin spindle 
protein (KSP), functions by ensuring proper separation of microtubules to facilitate 
proper bipolar arrangement of the spindle (94,112). Monastrol, a small molecule able to 
reversibly and allosterically inhibit Eg5’s ATPase activity (94,112). Eg5 inhibition leads 
to formation of monopolar spindles and a significant mitotic arrest in all mitotic cells 
(94). Mitotic arrest is followed by subsequent chromosomal decondensation and 
reversion to interphase or cell death (94). However, in tetraploid cells, there was no such 
arrest; instead, there was actually a shortening of metaphase and these tetraploid cells 
progressed through an often abnormal and asymmetric division, thus leading to decreased 
viability in subsequent progeny (94,112). Interestingly, Monastrol, an Eg5 inhibitor, also 
inhibits via binding allosterically on loop 5, similar to the inhibition by BTB-1 for 
KIF18A; the distinction being, Monastrol maintains the capacity to bind non-microtubule 
bound variants (95,112). Additionally, Watts et al. (2013) found high similarity in the 
loop 5 binding cleft of KSP for another mitotic motor KIFC1 or HSET, which they used 
to screen for possible inhibitors and found the compound CW069 (75). HSET was shown 
to generate bipolar spindles specifically in cells with extra centrosomes, and inhibition of 




 In summary, KIF18A is a desirable target for an effective small molecule 
inhibitor that can adequately reproduce KIF18A knockdown’s effects on mitosis. Due to 
increased dependence secondary to alignment errors, missegregation, lagging 
chromosomes, and micronuclei formation, KIF18A inhibitions has been demonstrated to 
have profound effects on tetraploid cells while sparing diploid cells. Additionally, 
KIF18A is significantly overexpressed in cancers while non-essential in normal cells 
(84). The loop 5 segment remaining a known point of interaction among KIF18A and 







Breast cancer cell line HCC1806 were purchased previously from ATCC and 
transduced with lentivirus carrying H2B-GFP to stably express a H2B-GFP fusion 
protein. These cells were maintained as previously described (84). In short, cells were 
kept in a controlled atmosphere environment held at 37°C with 5% humidified CO2. 
HCC1806 H2B-GFP were maintained in RPMI (Gibco) (ThermoFisher Scientific, MA) 
supplemented with 10% FBS and 100 IU/mL penicillin and 100 μg/mL streptomycin 
(84). 
Identification of Potential Inhibitors 
Through our collaboration with Professor John Porco, PhD, Boston University 
Center for Molecular Discovery, and Professor Lauren E. Brown, PhD, Boston 
University Center for Molecular Discovery, Schrodinger’s Glide (Schrodinger, LLC, NY) 
was used to dock the full BU-CMD collection. Schrodinger’s Glide is a “grid-based 
ligand docking with energetics” software that allow for rapid computation and analysis of 
potential protein-drug interactions based on known orientation, position, and 
conformation of proteins and substrates (115,116). The targeted region of KIF18A 
(independent selection and methodology by Dr. Brown) was the 5LRE crystal structure, 
with a 50GC cryo-EM structure being the most suitable for docking (114). From the 
above processes, a 600-compound diversity set was generated and a randomly selected 
subsection of 80 compounds was investigated. An example of a suspected compound 
with associated 2D/3D visualization can be seen in Appendix 1. 
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Preparation of Compound Stock 
 All compounds from the above inhibitor screen were dissolved in a volume of 
dimethyl sulfoxide (DMSO) required to generate a 10-20 mM stock. No visible 
precipitation was noted, and the compounds were subsequently stored at -80° C until 
requisite use.  
siRNA Sequences 
KIF18A (Silencer Select s37882 – Ambion) 5’-UCUCGAUUCUGGAACAAGCAG-3’ 
(97). 
siRNA Transfections 
Following protocol from Quinton et al. (2021), siRNA transfections used Lipofectamine 
RNAiMAX (ThermoFisher, MA) as per manufacturer instructions. Final siRNA 
concentration used in the media was 10 nM. Cells were transfected for 24 hours and then 
media was replaced with siRNA free media.  
Live Cell Imaging 
Live cell imaging was preformed following protocols from Quinton et al. (2021) 
and Bolgioni et al. (2018). In brief, HCC1806-H2BGFP were cultured as previously 
described.  HCC1806-H2BGFP cells were plated onto a glass-bottom optical 96-well 
tissue culture plate (ThermoFisher, MA) at a cellular concentration of 10,000 cells per 
well in 100 μL of RPMI culture media, supplemented as above. At time of plating, cells 
in a specified positive control well were reverse transfected with siRNA (siKIF18A) as 
indicated above to a final concentration of 10 nM siKIF18A. Cells were allowed to 
proliferate for 24 hours in an atmosphere-controlled environment (37° C with 5% 
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humidified CO2). At 24 hours, confluence was verified via light-microscopy. If cells were 
below 70% confluence, they were allowed to proliferate further until they reached that 
threshold except for the positive control siKIF18A well which would have its media 
replaced with 200 μL of fresh RPMI media at the 24-hour mark regardless of confluence.  
At the correct confluence threshold, the well with positive control siKIF18A was 
replaced with 200 μL of fresh RPMI media and 200 uL of 50 μM final concentration 
drugs were added to any the screening wells. Drug solvent, DMSO, was kept at or below 
1.0% by volume unless otherwise stated. Additional control wells were generated as 
follows: a DMSO control gradient of 0.5, 0.75, and 1.0% by volume DMSO; 100 μM 
Monastrol solubilized in <1% DMSO by volume.  
After proper replacement/addition, imaging was performed using a Nikon Ti-E 
inverted microscope with a Perfect-Focus-System (Nikon, Tokyo) and an Andor Zyla 4.2 
Plus (Andor Technology, CT) digital camera. The 96-well plate was secured in an 
environmentally controlled chamber (37°C with humidified 5% CO2) encasing the 
camera apparatus. Fluorescent images were obtained at 10-minute intervals for 48 hours 
using the 10x (0.3 NA) objectives at multiple points. Captured images were analyzed as 
described below. 
Automated Cell Count Protocol 
 At the conclusion of the 48-hour imaging window, captured frames were analyzed 
for several factors using NIS Elements AR Software. The first factor was overall cell 
count at time periods: 1 hour post onset of imaging, 3 hours post onset of imaging, and 
every 3 hours thereafter until 48 hours (ex. 6, 9, 12, …). At each time point, Nikon 
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Elements AR Object Count feature was utilized to optimize the process. Using the Object 
Count, thresholds of 634 and 912 for lower and upper limits were used for the range of 
intensities and a minimum area of 0.83 microns was used to exclude cellular debris. A 












Figure 5: Automated Cell Count by Nikon Elements AR 
 
The same image before and after threshold specific cell counting. A: No cell counting 
feature and red bar indicates 100-micron distance. B: Red and Green indicate varying 
levels of intensity (green being saturated intensity levels). Any counted cell will have a green 
border in the NIS Elements AR window. Excluded cells will have a blue border. C: Zoomed 
in region of image without counting feature and same 100-micron scale bar at bottom. D: 
Same image from C except counting feature activated denoting correct identification of 
counted cells (green outline).  
Threshold for Screened Compounds 
 After generation of the respective cell counts at each time point as indicated 
above, this was normalized to the initial starting count at time t=1. Additionally, the 







the various control groups. A protocol similar to Donovan et al., (2020), was used for 
identification of mitotic figures and is reproduced in brief: loosely-to-densely packed 
chromosomal content indicative of prophase, protruding spikes/rods indicative of 
prometaphase, aligned chromosomal content indicative of metaphase, separation 
(bi/multipolar) from a metaphase arrangement indicative of anaphase, distinction and 
decondensation of daughter nuclei indicative of telophase/cytokinesis (113). These values 
were then used to formulate a mitotic index, which would be the second screening criteria 
for any compound that appeared to increase its mitotic index relative to control values 
(DMSO).  
I have tested a total of 80 compounds from the 600-compound screening library. 
Initially, fold-change was calculated at time points 1, 12, 24, 36, and 48 hours identical to 
above. A threshold was then set at the fold-change increase of siKIF18A and any 
compound which had a fold-increase that was below this level was then evaluated for 
mitotic figures and the mitotic index was generated. A statistically significant increase in 
mitotic index was then further analyzed by calculating the duration of mitosis via Nikon 
Elements AR Software (Nikon, Tokyo). Mitotic duration was defined as the frame at time 
of visible condensation of nuclear components until the frame in which a “final mitotic 
event” occurs. These final mitotic events include mitotic slippage, cell death in mitosis, 
or completion of mitosis via cytokinesis.  
Statistical Analysis 
 Most experiments were performed as a technical duplicate and analyzed using 
GraphPad Prism 7 Software (GraphPad Software, CA). Simple and repeat measures one-
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way ANOVA, two-way ANOVA, and ANOVAs with either Dunnett’s or Tukey’s 
Multiple Comparison Test were used to compare the differences of continuous variable 







 To identify compounds that may inhibit KIF18A, we treated H2B-GFP cells with 
an array of small molecules (50 μM concentration) that were dissolved in DMSO solvent 
on a glass-bottom 96-well plate. The cells were plated at density of approximately 10,000 
cells per well, treated with the compounds after 24 hours from initial plating, and then 
immediately imaged for 48 hours in a temperature-controlled environment. Controls 
included wells with DMSO only (at similar volume % to drug treated wells), Monastrol 
(100 μM final concentration), and siRNA knockdown of KIF18A (10 nM final 
concentration). Monastrol, an inhibitor of Kinesin-5 family member Eg5, was selected as 
a positive control as it demonstrates non-specific mitotic inhibition in all effected cells; 
its phenotype being a monopolar spindle and mitotic arrest. At the conclusion of imaging, 
cell counts were estimated with automated cell counting software. The change in cell 
count was normalized to initial cell counts and the fold increase is represented below in 

























Figure 6: Fold Increase in Cell Count for Various Conditions. 
 
HCC1806 H2B-GFP were plated in a 96-well plate under a range of conditions, the controls 
for which are represented in the above legend. Each data point represents the mean of a 
technical duplicate. Bars denote standard deviation for the given data set. 
 
As can be seen below in Tables 2 and 3, there was a mild yet statistically 
significant difference between the differing concentrations of DMSO. Perhaps this could 
be due to the organic solvent not being tolerated well by the seeded cells; however, this is 
not necessarily the most likely explanation as it does not appear to be a gradient effect 
based on concentration of DMSO dosage (0.75% > 0.5 % > 1.0% in absolute fold change 
over 48 hours). Monastrol and siKIF18A showed statistically significant reduction in 
fold-increase over the 48-hour period compared to almost all concentrations of DMSO 
(siKIF18A having a non-significant increase compared to 1.0% DMSO). Additionally, 





Table 2: Means of Fold Change for Given Treatment Options.  
 
Normalized value to starting cell count at 1 hour after onset of imaging. Monastrol 
concentration was 100 μM. siKIF18A reverse transfection for 24 hours at final siRNA 
concentration of 10 nM. Numbers indicate an average of a technical duplicate at given time 
point as indicated by leftmost column.  
Hours 0.50% DMSO 0.75% DMSO 1.00% DMSO Monastrol siKIF18A 
1:00:00 1.000 1.000 1.000 1.000 1.000 
3:00:00 1.026 1.036 1.059 1.002 1.015 
6:00:00 1.050 1.051 1.098 0.9748 1.076 
9:00:00 1.103 1.139 1.149 0.9855 1.131 
12:00:00 1.197 1.197 1.201 0.9967 1.189 
15:00:00 1.317 1.277 1.183 1.203 1.052 
18:00:00 1.393 1.363 1.313 1.231 1.057 
21:00:00 1.444 1.438 1.318 1.240 1.136 
24:00:00 1.477 1.490 1.384 1.237 1.239 
27:00:00 1.521 1.513 1.377 1.281 1.282 
30:00:00 1.508 1.533 1.416 1.269 1.412 
33:00:00 1.574 1.617 1.464 1.307 1.367 
36:00:00 1.569 1.626 1.492 1.305 1.387 
39:00:00 1.588 1.620 1.488 1.337 1.449 
42:00:00 1.637 1.721 1.510 1.386 1.506 
45:00:00 1.635 1.708 1.538 1.324 1.519 




Table 3: Repeat Measures One-Way Anova with Tukey’s Multiple Comparison Test 
Reflecting Differences in Fold-Increase for Treatment Options.  
 
% DMSO is by Volume. Monastrol at concentration of 100 μM. siKIF18A at concentration 
of 10 nM for 24 hours before media replacement. Notations: ns = no significance; ** = p-
value < 0.01; *** = p-value < 0.001; **** = p-value < 0.0001. 
Tukey's multiple comparisons test Mean Diff. Summary Adjusted P Value 
0.5% DMSO vs. 0.75% DMSO 
-0.01860 
ns 0.1988 
0.5% DMSO vs. 1.0% DMSO 
0.07230 
** 0.0053 
0.5% DMSO vs. Monastrol 
0.1949 
**** <0.0001 
0.5% DMSO vs. siKIF18A 
0.1350 
** 0.0019 
0.75% DMSO vs. 1.0% DMSO 
0.09090 
** 0.0024 
0.75% DMSO vs. Monastrol 
0.2135 
**** <0.0001 
0.75% DMSO vs. siKIF18A 
0.1536 
*** 0.0004 
1.0% DMSO vs. Monastrol 
0.1226 
**** <0.0001 
1.0% DMSO vs. siKIF18A 
0.06267 
ns 0.0542 














Figure 7: Mitotic Duration for Control Conditions.  
 
Each of the control condition was treated as mentioned above. Using Nikon Elements AR 
Software, the duration of mitosis was calculated for 50 independents event per condition. 
Each dot represents a unique event. Red bars indicate mean whereas adjacent black bars 
indicate a single standard deviation. * denotes significance compared to all three DMSO 
controls; ns = no significance.  
The mitotic duration was then compared for the different treatment options, which 
is reflected above in Figure 7. Both Monastrol and siKIF18A were found to have 
statistically significant prolongation of mitosis, consistent with previous studies 
mentioned in the introduction. 
As reflected below in Table 4, there was a statistically significant increase in 
mitotic duration for both Monastrol and siKIF18A, both consistent with expected results. 
Monastrol did have a higher mitotic duration than siKIF18A; however, it was just shy of 
being significant (p-value = 0.0535). It appears that DMSO concentration in the tested 





Table 4: Mitotic Duration One-Way Anova Tukey’s Multiple Comparison Test. 
 
Mean mitotic duration for different control treatments. **** denotes highly significant 
difference. *** denotes significant difference. ns = no significance.  
Tukey's multiple comparisons test Mean Diff. Summary Adjusted P Value 
0.5% DMSO vs. 0.75% DMSO 50 ns 0.7372 
0.5% DMSO vs. 1.0% DMSO 47.2 ns 0.7764 
0.5% DMSO vs. siKIF18A -205.2 **** <0.0001 
0.5% DMSO vs. Monastrol -316.4 **** <0.0001 
0.75% DMSO vs. 1.0% DMSO -2.8 ns >0.9999 
0.75% DMSO vs. siKIF18A -255.2 **** <0.0001 
0.75% DMSO vs. Monastrol -366.4 **** <0.0001 
1.0% DMSO vs. siKIF18A -252.4 **** <0.0001 
1.0% DMSO vs. Monastrol -363.6 **** <0.0001 




Control conditions were as expected for the underlying system, so analysis of the 
investigated compounds continued. As mentioned in the methods, all screened 
compounds were previously administered at 50 μM concentration and imaged over the 
48-hour window. Due to the mitotic prolonging, one would expect there to be a decrease 
in overall growth rate compared to negative controls. As such, a threshold was made at 
siKIF18A’s 48-hour fold-change (1.613) to which all other compounds were compared at 
the same time point.  
Figure 8: Fold Increase for Controls and Subsection of Compounds. 
 
Each point reflects the average fold change for a duplicate measurement of corrected cell 
counts at a given time point reflected on the axis. All compounds that had a final 48-hour 
fold increase below the 48-hour fold increase of siKIF18A were codified into Compounds 1-
19, reflected by the numbers 1-19 in the legend. * denotes statistical significance at p<0.05; 
ns = no significance. 
 As noted above, there are differences in relative fold-change at the 48-hour point 
(with compounds 6 and 13 showing the only statistically significant differences at t=48 















































hours [p-values of 0.0618, 0.0229*, 0.0415*, 0.0150*, for 0.5% DMSO vs Compound 6, 
0.5% DMSO vs Compound 13*, 0.75% DMSO vs Compound 6*, 0.75% DMSO vs 
Compound 13*, respectively]; * denotes statistical significance), the overall differences 
are entirely not statistically significant—likely due to the small sample size and lack of 
statistical power therein. Regardless, decreases in viability can be from a wide range of 
intracellular or extracellular mechanisms, and this research is currently focused on 
mitotic-related viability changes, not overall viability changes. To account for this, 
mitotic indices were generated for the compounds and visualized below in Figure 9.  
Figure 9: Mitotic Indices for Compounds and Controls. 
 
Mitotic indices were generated via hand analysis for quantification of total number of 














































count figures generated by the automated cell count. Height of the column denotes average 
mitotic index, and the bars denote one standard deviation. * denotes statistical significance 
at p<0.05 for Monastrol, siKIF18A, and Compound 3 compared to all three DMSO control 
conditions.  
 While Compounds 6 and 13 are effective in possibly lowering the proliferation 
and fold-increase of the HCC1806 cancer cells, the mechanism does not appear to be due 
to an arrested mitosis as there is no expected buildup of mitotic figures that would 
increase the index. As such, they will not be examined further in this report. As can be 
seen below in Figure 10 and Table 5, the addition of Compound 3 appears to have 
significantly increased the duration of mitosis for many of the cycling cells while also 
slowing the overall propagation of the cell line. Interestingly, Compound 3 does not 
appear to affect mitotic length for all cells in the population whereas the nonspecific 
inhibitor Monastrol appears to prolong mitosis in all cells compared to DMSO control. 
This bodes well for the possible specificity of Compound 3, as we would expect a 
compound that is causing non-specific mitotic arrest to be coinciding with a longer 




Figure 10: Mitotic Duration with Compound 3. 
 
As previously described, each circle is a unique mitotic event. N=50. Red bars denote 
averages and T-shaped bars denote one standard deviation. siKIF18A final concentration 























































Table 5: Mitotic Duration One-Way ANOVA. 
Tukey's multiple comparisons test Mean Diff. Summary Adjusted P Value 
0.5% DMSO vs. 0.75% DMSO 50 ns 0.8491 
0.5% DMSO vs. 1.0% DMSO 47.2 ns 0.8779 
0.5% DMSO vs. siKIF18A -205.2 **** <0.0001 
0.5% DMSO vs. Monastrol -316.4 **** <0.0001 
0.5% DMSO vs. Compound 3 -144.2 * 0.0104 
0.75% DMSO vs. 1.0% DMSO -2.8 ns >0.9999 
0.75% DMSO vs. siKIF18A -255.2 **** <0.0001 
0.75% DMSO vs. Monastrol -366.4 **** <0.0001 
0.75% DMSO vs. Compound 3 -194.2 *** 0.0001 
1.0% DMSO vs. siKIF18A -252.4 **** <0.0001 
1.0% DMSO vs. Monastrol -363.6 **** <0.0001 
1.0% DMSO vs. Compound 3 -191.4 *** 0.0001 
siKIF18A vs. Monastrol -111.2 ns 0.0979 
siKIF18A vs. Compound 3 61 ns 0.7075 




 To support these findings, the experiment was repeated with increased dosage of 
Compound 3 (100 μM and 75 μM) and the same controls. The corresponding fold-









Figure 11: Fold-Increase Controls vs Compound 3.  
 
Similar to previous. Each point reflective of an averaged normalized cell count from a 
technical duplicate.  
 The data seems to be mildly inconsistent in comparison to the previous 
experiment, due to the unabated proliferation of siKIF18A cells and decreasing viabilities 
of DMSO controls over time. This could be driven by an overall decrease in viability 
among all control conditions beginning around the 24-hour mark (noted by the fall in cell 
count over time in control DMSO which is also noted in a sharp drop off in mitotic index, 
both unseen in previous experiment) and perhaps incomplete depletion of KIF18A among 
the overall population. Given the near uniform decrease in all DMSO control groups, this 
is likely an exogenous environmental factor not necessarily related to treatment 
conditions. 
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Table 6: Repeat Measures One-Way ANOVA Fold-Increase. 
Tukey's multiple comparisons test Mean Diff. Summary Adjusted P Value 
0.5% DMSO vs. 0.75% DMSO -0.04493 ns 0.749 
0.5% DMSO vs. 1.0% DMSO -0.0978 ns 0.0662 
0.5% DMSO vs. siKIF18A -0.2289 ns 0.2692 
0.5% DMSO vs. Monastrol 0.07513 ns 0.8801 
0.5% DMSO vs. 100 μM Compound 3 0.2733 *** 0.0002 
0.5% DMSO vs. 75 μM Compound 3 0.1243 ns 0.0574 
0.75% DMSO vs. 1.0% DMSO -0.05287 **** <0.0001 
0.75% DMSO vs. siKIF18A -0.1839 ns 0.1514 
0.75% DMSO vs. Monastrol 0.1201 * 0.0446 
0.75% DMSO vs. 100 μM Compound 3 0.3182 **** <0.0001 
0.75% DMSO vs. 75 μM Compound 3 0.1692 **** <0.0001 
1.0% DMSO vs. siKIF18A -0.1311 ns 0.4709 
1.0% DMSO vs. Monastrol 0.1729 ** 0.0041 
1.0% DMSO vs. 100 μM Compound 3 0.3711 **** <0.0001 
1.0% DMSO vs. 75 μM Compound 3 0.2221 **** <0.0001 
siKIF18A vs. Monastrol 0.304 **** <0.0001 
siKIF18A vs. 100 μM Compound 3 0.5021 *** 0.0003 
siKIF18A vs. 75 μM Compound 3 0.3531 ** 0.0015 
Monastrol vs. 100 μM Compound 3 0.1981 ** 0.0029 
Monastrol vs. 75 μM Compound 3 0.04915 ns 0.6115 
100 μM Compound 3 vs. 75 μM 
Compound 3 -0.149 **** <0.0001 
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 As noted in the table above, 100 μM Compound 3 appears to have a statistically 
significant (p-value < 0.0002) reduction in fold-change compared to all other treatment 
conditions. 75 μM Compound 3 on the other hand does not appear to show a statistically 
significant reduction only in comparison to 100 μM Compound 3, 100 μM Monastrol, 
and narrowly with 0.50% DMSO. 
 Similar to before, mitotic indices were generated at time points: 1, 12, 24, 36, and 
48 hours. Mean differences between as tested by a repeat measures one-way ANOVA 
(see Table 7 below) demonstrated no overall significant difference in mitotic index 
between all treatment options. This appears to be largely due to the aforementioned 
generalized viability deficit which could be externally driven. As such, a two-way 
ANOVA was implemented to determine statistically significant differences in mitotic 
index at each individual time point—the results can be seen below in Table 8. 
Interestingly, by 12 hours post-onset of imaging/drug application, 100 μM and 75 μM 
Compound 3 show statistically significant increases in mitotic index compared to all 
DMSO control conditions; however, this elevation is transiently significant and lost upon 
the next point of image analysis. Monastrol maintains a statistically significant increase 
in mitotic index compared to two or more DMSO control conditions at all time points, 
while siKIF18A demonstrates a statistically significant increase in mitotic index 
compared to controls in most conditions starting at 24 hours post-imaging, with further 
increases at 36 hours post-imaging indicating a latent rise in mitotic burden as seen in 




Table 7: Repeat measures One-Way ANOVA Mitotic Index. 
Tukey's multiple comparisons test Mean Diff. Summary Adjusted P Value 
0.5% DMSO vs. 0.75% DMSO -0.0037 ns 0.4941 
0.5% DMSO vs. 1.0% DMSO 0.001489 ns 0.9045 
0.5% DMSO vs. siKIF18A -0.0173 ns 0.5541 
0.5% DMSO vs. Monastrol -0.03692 ns 0.1422 
0.5% DMSO vs. 100 μM Compound 3 -0.01552 ns 0.8276 
0.5% DMSO vs. 75 μM Compound 3 -0.01028 ns 0.1992 
0.75% DMSO vs. 1.0% DMSO 0.005193 * 0.0408 
0.75% DMSO vs. siKIF18A -0.01359 ns 0.632 
0.75% DMSO vs. Monastrol -0.03322 ns 0.2461 
0.75% DMSO vs. 100 μM Compound 3 -0.01181 ns 0.956 
0.75% DMSO vs. 75 μM Compound 3 -0.00658 ns 0.799 
1.0% DMSO vs. siKIF18A -0.01879 ns 0.3659 
1.0% DMSO vs. Monastrol -0.03841 ns 0.1515 
1.0% DMSO vs. 100 μM Compound 3 -0.017 ns 0.8174 
1.0% DMSO vs. 75 μM Compound 3 -0.01177 ns 0.274 
siKIF18A vs. Monastrol -0.01962 ns 0.8782 
siKIF18A vs. 100 μM Compound 3 0.001783 ns >0.9999 
siKIF18A vs. 75 μM Compound 3 0.00702 ns 0.9923 
Monastrol vs. 100 μM Compound 3 0.0214 ns 0.0738 
Monastrol vs. 75 μM Compound 3 0.02664 ns 0.1501 




Table 8: Two-Way ANOVA with Tukey’s Multiple Comparisons Test Mitotic Index.  
 
Only statistically significant values have been reflected in the table. 
Tukey's multiple comparisons test Mean Diff. Summary Adjusted P Value 
Hour 1 
0.5% DMSO vs. Monastrol -0.01452 * 0.0366 
1.0% DMSO vs. Monastrol -0.01886 ** 0.0028 
Hour 12 
0.5% DMSO vs. Monastrol -0.07388 **** <0.0001 
0.5% DMSO vs. 100 μM Compound 3 -0.063 **** <0.0001 
0.5% DMSO vs. 75 μM Compound 3 -0.02315 *** 0.0002 
0.75% DMSO vs. Monastrol -0.07536 **** <0.0001 
0.75% DMSO vs. 100 μM Compound 
3 -0.06448 **** <0.0001 
0.75% DMSO vs. 75 μM Compound 3 -0.02463 **** <0.0001 
1.0% DMSO vs. Monastrol -0.07873 **** <0.0001 
1.0% DMSO vs. 100 μM Compound 3 -0.06785 **** <0.0001 
1.0% DMSO vs. 75 μM Compound 3 -0.028 **** <0.0001 
siKIF18A vs. Monastrol -0.0823 **** <0.0001 
siKIF18A vs. 100 μM Compound 3 -0.07142 **** <0.0001 
siKIF18A vs. 75 μM Compound 3 -0.03157 **** <0.0001 
Monastrol vs. 75 μM Compound 3 0.05073 **** <0.0001 
100 μM Compound 3 vs. 75 μM 
Compound 3 0.03985 **** <0.0001 
Hour 24 
0.5% DMSO vs. siKIF18A -0.01865 ** 0.0032 
0.5% DMSO vs. Monastrol -0.03959 **** <0.0001 
0.75% DMSO vs. Monastrol -0.03227 **** <0.0001 
1.0% DMSO vs. siKIF18A -0.01945 ** 0.0019 
 
42 
1.0% DMSO vs. Monastrol -0.04038 **** <0.0001 
siKIF18A vs. Monastrol -0.02094 *** 0.0007 
Monastrol vs. 100 μM Compound 3 0.03021 **** <0.0001 
Monastrol vs. 75 μM Compound 3 0.03379 **** <0.0001 
Hour 36 
0.5% DMSO vs. siKIF18A -0.03624 **** <0.0001 
0.5% DMSO vs. Monastrol -0.02045 ** 0.001 
0.75% DMSO vs. siKIF18A -0.02809 **** <0.0001 
1.0% DMSO vs. siKIF18A -0.03389 **** <0.0001 
1.0% DMSO vs. Monastrol -0.01811 ** 0.0045 
siKIF18A vs. Monastrol 0.01579 * 0.018 
siKIF18A vs. 100 μM Compound 3 0.0348 **** <0.0001 
siKIF18A vs. 75 μM Compound 3 0.02997 **** <0.0001 
Monastrol vs. 100 μM Compound 3 0.01901 ** 0.0025 
Monastrol vs. 75 μM Compound 3 0.01418 * 0.044 
Hour 48 
0.5% DMSO vs. siKIF18A -0.03725 **** <0.0001 
0.5% DMSO vs. Monastrol -0.03617 **** <0.0001 
0.75% DMSO vs. siKIF18A -0.03438 **** <0.0001 
0.75% DMSO vs. Monastrol -0.03329 **** <0.0001 
1.0% DMSO vs. siKIF18A -0.03705 **** <0.0001 
1.0% DMSO vs. Monastrol -0.03596 **** <0.0001 
siKIF18A vs. 100 μM Compound 3 0.03606 **** <0.0001 
siKIF18A vs. 75 μM Compound 3 0.0283 **** <0.0001 
Monastrol vs. 100 μM Compound 3 0.03498 **** <0.0001 




 Finally, as before, mitotic duration was quantified, and the results can be seen in 















Figure 12: Mitotic Duration Controls vs 100 and 75 μM Compound 3. 
 
Red bars are reflective of mean duration, error bars reflected in bracketing T shapes. N=50 
for each condition. 
As can be seen in both the figure and Table 8, Compound 3 appears to 
significantly prolong mitosis in a dose dependent manner. In this experiment, although 
mitosis was mildly prolonged with siKIF18A treatment, it was not to a level to reach 





































































Table 9: One-way ANOVA with Tukey’s Multiple Comparison Test for Mitotic Duration of 
Compound 3 and Controls. 
 
Compound 3 was solubilized in DMSO bringing the final volume in the treated well to 1% 
and 0.75% for 100 μM and 75 μM Compound 3, respectively.  
Tukey's multiple comparisons test Mean Diff. Summary Adjusted P Value 
0.5% DMSO vs. 0.75% DMSO 7.4 ns >0.9999 
0.5% DMSO vs. 1.0% DMSO 3.2 ns >0.9999 
0.5% DMSO vs. siKIF18A -103.2 ns 0.2296 
0.5% DMSO vs. Monastrol -249 **** <0.0001 
0.5% DMSO vs. 100 μM Compound 3 -295.8 **** <0.0001 
0.5% DMSO vs. 75 μM Compound 3 -177.6 ** 0.0014 
0.75% DMSO vs. 1.0% DMSO -4.2 ns >0.9999 
0.75% DMSO vs. siKIF18A -110.6 ns 0.1609 
0.75% DMSO vs. Monastrol -256.4 **** <0.0001 
0.75% DMSO vs. 100 μM Compound 3 -303.2 **** <0.0001 
0.75% DMSO vs. 75 μM Compound 3 -185 *** 0.0007 
1.0% DMSO vs. siKIF18A -106.4 ns 0.1978 
1.0% DMSO vs. Monastrol -252.2 **** <0.0001 
1.0% DMSO vs. 100 μM Compound 3 -299 **** <0.0001 
1.0% DMSO vs. 75 μM Compound 3 -180.8 ** 0.001 
siKIF18A vs. Monastrol -145.8 * 0.0182 
siKIF18A vs. 100 μM Compound 3 -192.6 *** 0.0003 
siKIF18A vs. 75 μM Compound 3 -74.4 ns 0.6268 
Monastrol vs. 100 μM Compound 3 -46.8 ns 0.9392 
Monastrol vs. 75 μM Compound 3 71.4 ns 0.6716 




 Compound 3 at a concentration of 100 μM demonstrated statistically significant 
prolongation of mitosis compared to all control treatment conditions except for 100 μM 
Monastrol, to which it showed no significant difference. In further support, as per Figure 
13 below, still images of mitotic cells show the expected hyperoscillating-phenotype with 
missegregated chromosomes. This coupled with the significant reduction in growth 
demonstrated earlier provides further evidence of a potential therapeutic value to 




Figure 13: Missegregated Chromosomes in Compound 3 Treated HCC1806 Cell. 
 
Images reflect still images of HCC1806 that are visible via H2B-tagged with GFP and 
fluorescent microscopy. Green reflects GFP tagged to H2B, thus highlight genetic material. 
Red arrows indicate the same cell undergoing mitosis in subsequent 10 minute interval steps 
(denoted T=#, where each # denotes how many 10 minute steps from initial time of image 
have occurred; T=0 denotes initial image capture). Blue arrows highlight genetic material 
that is not properly aligned to the metaphase plate.  
  
T = 0 
T = 1 
T = 2 
T = 3 






 Several small molecule inhibitors targeted to modifying spindle/microtubule and 
mitotic dynamics have been developed and implemented clinically, such as Taxol (100). 
Despite their proven efficacy at decreasing cancer viability, their inability to consistently 
and selectively target only cancerous phenotypes makes them prone to unfortunate side-
effect (100). As such, finding a mechanism to target unique and cancer-specific 
vulnerabilities has remained a topic of active research. Kinesins, due to their active 
interactions with microtubules and significant roles in mitotic processes, have become 
ever increasing targets for further investigation (61,62). As mentioned previously, 
KIF18A inhibition has been identified as an attractive chemotherapeutic target due to the 
preferential invocation of WGD/high aneuploidy specific vulnerability. In large part due 
to significantly elongated spindle fibers and hyperoscillating phenotype, aneuploid/WGD 
tumor cells become prone to lagging chromosomes, segregation errors, micronuclei 
formation, and other disadvantageous intracellular events (78,81-84). Although a KIF18A 
inhibitor is currently available, BTB-1 remains somewhat limited in its inability to 
phenocopy KIF18A knockdown spindle dynamics (74,76,77).  
Further Investigation of Compound 3 
 As of now, Compound 3 has been proven to show phenotypical similarities to 
knockdown of KIF18A—prolonged mitosis and decreased general viability denoted by a 
slowing of growth (low fold-increase over 48-hour window). Additionally, it appears to 
have the hyperoscillating/missegregated chromosomes that one would expect to find with 
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a KIF18A deficient cell, lending further evidence to its successful inhibition of the 
intended target (see Figure 13 above). Excitingly, Compound 3 does not appear to arrest 
all cells in mitosis, suggesting that it may have some specificity and not be a general 
mitotic inhibitor—such as Monastrol.  
There are further investigative steps that need fulfilling regarding Compound 3. 
Although it is suspected to interact with KIF18A due to selection via Schrodinger’s Glide 
and similar phenotypic effects, verification of this interaction would be advantageous. 
Given the generally similar structure of many kinesins, it remains a possibility that it is 
interacting with other mitotic kinesins, such as Eg5, or other intracellular targets yet to be 
identified. There are similarities in both mitotic index data and fold-increase graphs that 
suggest Compound 3 could have a Monastrol-like effect; however, as seen in Figure 13, 
cells treated with Compound 3 in large part maintain bipolar spindle orientation—cells 
treated with Monastrol largely do not. To investigate this process and seek clarity, one 
could replicate the protocols of Locke et al., Catarinella et al., or Braun et al. through use 
of recombinant KIF18A and investigating ATPase activity when in the presence/absence 
of microtubules and other requisite substrates after treatment with Compound 3 
(74,76,77). In short, to verify kinetics, recombinant motor domain of KIF18A 
(Glutathion-S-Transferase KIF18A or GST-KIF18A) can be titrated with increasing 
amounts of Compound 3 and amount of ATP-hydrolysis can be quantified to determine 
% inhibition, an IC50 value can be estimated with titration of increasing does of 
Compound 3 in the presence of microtubules, and competitive inhibition can be 
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determined by fitting varying concentrations of ATP and Compound 3 in the presence of 
KIF18A and saturating amounts of microtubules to the Michaelis-Menten equation (77). 
 Part of the allure of pursuing KIF18A inhibition is the WGD/high aneuploid 
conferred dependence on its activity. As such, for Compound 3 to have the intended 
effects, one would expect it to preferentially cause viability defects in WGD/high 
aneuploid cells. Along this avenue, an isogenic system where Compound 3 can be 
administered to both diploid and tetraploid variants of the same cell line (as used in 
Quinton et al.), would reveal any potential for tetraploid/WGD/high aneuploid specific 
effects of Compound 3 (84).  
 Finally, immunofluorescent staining could be used to investigate whether there 
are significant structural changes to key architectural constituents such as centrosomes or 
microtubules, which might further elucidate the mechanism of action through which 
Compound 3 was able to prolong mitosis and decrease fold-change after administration.  
Conclusion 
In summary, using a fluorescent-H2B-GFP-tagged breast cancer cell line, we 
developed a live-cell imaging assay to investigate potential KIF18A inhibitor from a 
range of suspected interacting molecules. From the initial screen, we were able to identify 
a selection of compounds that were able to decrease fold-increase in cultured HCC1806 
cells. Among these, mitotic index was utilized as a secondary threshold to ensure that 
viability changes were reflective of the intended prolonged-mitosis phenotype. Of the 
initial fold-decreasing compounds (18 total), only one was found to significantly increase 
mitotic index: Compound 3. Compound 3 was both further analyzed and retested at 
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higher concentrations and found to significantly increase mitotic length, compared to 
DMSO controls, while also reproducing phenotypical changes (missegregated 
chromosomes) expected for KIF18A inhibition. Compound 3 now presents as an exciting 








Appendix 1: Representative Docking Hit. 
 
Provided by Dr. Lauren, Boston University, reflecting the suspected interaction of the small molecule inhibitor 
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